Image by Adeolu Eletu

PRESS RELEASE

Longeveron Recruiting for Stem Cell Alzheimer’s Trial in South Florida

 

May 23, 2018

 

Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for age-related diseases, announced that it is currently recruiting for a Phase 1 clinical trial to evaluate the safety and efficacy of its allogeneic Mesenchymal Stem Cells (MSCs) in patients with Alzheimer’s disease.  The randomized, placebo-controlled, double-blinded trial is seeking up to 30 participants and is being conducted at the University of Miami Miller School of Medicine, Miami Jewish Health Systems, and Brain Matters Research in Delray Beach, Florida

 

NEWS PROVIDED BY
 

Longeveron LLC 
 

May 23, 2018 09:49 ET
 

MIAMI, May 23, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for age-related diseases, announced that it is currently recruiting for a Phase 1 clinical trial to evaluate the safety and efficacy of its allogeneic Mesenchymal Stem Cells (MSCs) in patients with Alzheimer’s disease.  The randomized, placebo-controlled, double-blinded trial is seeking up to 30 participants and is being conducted at the University of Miami Miller School of Medicine, Miami Jewish Health Systems, and Brain Matters Research in Delray Beach, Florida.

 

Eligible participants should be between 50 and 80 years old, be diagnosed with Alzheimer’s in accordance with established criteria, and have an identified adult caregiver.  Longeveron’s research is supported by the Alzheimer’s Association Part the Cloud Challenge on Neuroinflammation.

 

Longeveron’s MSC product is derived from the bone marrow of young, healthy donors and is currently being tested in a variety of indications in clinical trials, including Aging Frailty.  In 2017, the company published positive Phase I and Phase 2 Aging Frailty study results in the Journals of Gerontology.  Frail patients showed marked improvement in physical performance, lung function and inflammation biomarkers, with no serious adverse effects attributed to the treatment.

 

“Regenerative medicine is the future.  Controlling inflammation in Alzheimer’s disease is the key to a breakthrough,” noted Mark Brody, M.D. of Brain Matters Research in Delray Beach, Florida, a site for the clinical trial.

 

Marc Agronin, M.D., geriatric psychiatrist and vice president of Behavioral Health and Clinical Research at Miami Jewish Health, said, “Alzheimer’s disease is one of the most pressing health care issues for aging individuals, and we need an effective treatment, if not a cure.  An innovative study such as the Longeveron stem cell clinical trial is an important and promising step forward.”

 

Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases.  In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease.  The company is now recruiting for an expanded Phase 2b Aging Frailty study.

 

Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients.  Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.

 

About Longeveron 

 

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014.  Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life.  The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund.  Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.

 

For more information about the clinical trials

Longeveron is sponsoring, visit ClinicalTrials.gov

or Longeveron’s website www.longeveron.com

 

SOURCE Longeveron LLC

 

Related Links

www.longeveron.com

________

  • Facebook
  • Twitter
  • LinkedIn

________________

_________

________

__________

_____________

_________

© Copyright 2021 Longeveron. All rights reserved.